Get ready to turbocharge your scientific team’s PBBM PBPK modeling technology with the latest version of GastroPlus®!
GPX™ The Next Level PBPK Platform
It’s here—the latest version of GastroPlus®, GPX. And this is your chance to see it in action.
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations
The equivalence of absorption rates and extents between generic drugs and their reference formulations is crucial for ensuring therapeutic comparability.
GastroPlus®X (GPX™) Product Brochure
GastroPlus X (GPX™) is a mechanistically based simulation software package that simulates intravenous and oral absorption, pharmacokinetics, drug-drug interactions and pharmacodynamics in humans and animals.
GastroPlus®X Release Notes
Over the past several years, the Simulations Plus team has been revolutionizing oral small molecule PBPK/PBBM modeling with one of the most significant changes in the GastroPlus platform to date.
Women in Science: Nancy Lin, Pharmacometrician I
In a world where only 30% of researchers are female, it’s critical to highlight the women who have built their careers in STEM and share their insights and advice with others.
Advancing Toxicity Predictions: A Review on in Vitro to in Vivo Extrapolation in Next-Generation Risk Assessment
As a key step in next-generation risk assessment (NGRA), in vitro to in vivo extrapolation (IVIVE) aims to mobilize a mechanism-based understanding of toxicology to translate bioactive chemical concentrations obtained from in vitro assays to corresponding exposures likely to induce bioactivity in vivo.
In Vitro In Vivo Extrapolation and Bioequivalence Prediction for Immediate-Release Capsules of Cefadroxil Based on a Physiologically-Based Pharmacokinetic ACAT Model
Physiologically based pharmacokinetic (PBPK) modeling is a mechanistic concept, which helps to judge the effects of biopharmceutical properties of drug product such as in vitro dissolution on its pharmacokinetic and in vivo performance.
Assessing and mitigating pH-mediated DDI risks in drug development – formulation approaches and clinical considerations
pH-mediated drug-drug interactions (DDI) is a prevalent DDI in drug development, especially for weak base compounds with highly pH-dependent solubility.
HSPiP, Computational, and Thermodynamic Model–Based Optimized Solvents for Subcutaneous Delivery of Tolterodine Tartrate and GastroPlus-Based In Vivo Prediction in Humans: Part I
Tolterodine tartrate (TOTA) is associated with adverse effect, high hepatic access, varied bioavailability, slight aqueous solubility, and short half-life after oral delivery.
Evaluation of the Dissolution Behavior of the Lysosomotropic Drug Amlodipine using Physiologically Based Biopharmaceutics Modeling (PBBM)
Amlodipine (AML) is a weak base drug (pKa 9.1, lop=2.96) belonging to class I of the BCS and therefore a candidate for biowaiver.
From Pipeline to Plant Protection Products: Using New Approach Methodologies (NAMs) in Agrochemical Safety Assessment
The human population will be approximately 9.7 billion by 2050, and food security has been identified as one of the key issues facing the global population.
QSP and Oncology: How QSP Modeling Can Accelerate Therapy Development for Solid Tumors
A major obstacle in drug development is the combinatorial complexity of available oncology therapies under development for solid tumors.
Can in vitro/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib
Upadacitinib, classified as a highly soluble drug, is commercially marketed as RINVOQ®, a modified-release formulation incorporating hydroxypropyl methylcellulose as a matrix system to target extended release throughout the gastrointestinal (GI) tract.
Prediction of physicochemical and pharmacokinetic properties of botanical constituents by computational models
Botanicals contain complex mixtures of chemicals most of which lack pharmacokinetic data in humans.
Effect of Food Composition on the PK of Isoniazid Quantitatively Explained Using Physiologically Based Biopharmaceutics Modeling
This work shows the utilization of a physiologically based biopharmaceutics model (PBBM) to mechanistically explain the impact of diverse food types on the pharmacokinetics (PK) of isoniazid (INH) and acetyl-isoniazid (Ac-INH).
Evaluation of the Dissolution Behavior of Etodolac Tablers Using Physiologically Based Biopharmaceutics Modeling (PBBM) Approach
Etodolac is a non-steroidal, anti-inflammatory, acidic molecule (pKa 4.65) with pH-dependent solubility and classified as a BCS class II drug [1].
Development of Mechanistic In Vitro-In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables
Long-acting injectable (LAI) formulations provide sustained drug release over an extended period ranging from weeks to several months to improve efficacy, safety, and compliance.